Implementation of the Cancer Moonshot Blue Ribbon Panel Recommendations



National Cancer Advisory Board February 15, 2017

Overall Goals of the Cancer Moonshot

- Accelerate progress in cancer, including prevention & screening
 - From cutting edge research to wider uptake of standard of care
- Encourage greater cooperation and collaboration
 - Within and between academia, government, and private sector
- Enhance data sharing

(Presidential Memo 2016)

Blue Ribbon Panel Goals

- Identify major scientific opportunities that are poised to be accelerated by additional emphasis and funding
- Develop recommendations of opportunities that would be pursued through the Cancer Moonshot
 - Final recommendations at www.cancer.gov/brp

Blue Ribbon Panel Recommendations

- A. Network for direct patient engagement
- B. Cancer immunotherapy translational science network
- C. Therapeutic target identification to overcome drug resistance
- D. Creation of a national cancer data ecosystem
- E. Fusion oncoproteins in pediatric cancer
- F. Symptom management research
- **G.** Precision prevention and early detection
- H. Retrospective analysis of biospecimens from patients treated with standard of care
- I. Creation of human tumor atlas
- J. Development of new enabling technologies

Cross Cutting Themes: Health disparities, prevention, technology development, data sharing, partnerships

Cancer Funding in 21st Century Cures Act

- The cancer research portion is named the Beau Biden Cancer Moonshot Initiative
- \$1.8 billion over 7 years
 - \$300 million for FY17
- "To support cancer research, such as the development of cancer vaccines, the development of more sensitive diagnostic tests for cancer, immunotherapy and the development of combination therapies, research that has the potential to transform the scientific field that has inherently higher risk, and that seeks to address major challenges associated with cancer."

FY17 Implementation of Blue Ribbon Panel Recommendations: Laying the Groundwork


- Fusion Oncoproteins in pediatric cancer
 - Gene Fusions in Pediatric Sarcomas (APRC) PA-17-138
- New Enabling Technologies
 - APTRC supplement program PA-17-143
 - Innovative and Applied Emerging Molecular Analysis
 Technologies in Cancer Research RFA-CA-17-010, 011, 012, 013
 - PDX development centers RFA-CA-17-003, 004
- Cancer Immunotherapy
 - Biomarker development labs (CIMAC) for adult and pediatric; RFA-CA-17-005, 006
 - Canine immunotherapy RFA-CA-17-001, 002
 - Expand CIMAC to include pediatrics NOT-CA-17-024, 025
 - Autoimmune sequelae with NIAID (to be issued)

- Therapeutic Target Identification to Overcome
 Drug Resistance RFA-CA-17-009
- Prevention and Early Detection
 - HPV trial (DCEG-Gates Foundation)
 - Tobacco cessation supplements to Cancer Centers
- Symptom Management Research
 - Oral anticancer agents PA-17-060, 061

Beyond FY17: FY18 and FY19

Implementation of Blue Ribbon Panel Recommendations

Process for Implementation of BRP Recommendations




Cancer Moonshot Implementation Teams Aligned with BRP Recommendations

Charge to Cancer Moonshot Implementation Teams

- Discuss approaches and develop initiatives for FY18 and FY19 that will achieve the goals of the Recommendation
 - Identify gaps and opportunities in current landscape of existing initiatives
 - Seek input from others, including the cancer research community, advocates, and associations
 - Work with the Partnership Committee to consider creating and/or leveraging partnerships (academia, industry, pharma, ...)
- Provide oversight and coordination of the Team's funded initiatives (e.g managing awards, organizing meetings, providing supplements)

Process for Implementation of BRP Recommendations



Cancer Moonshot Implementation Teams (CMIT) Aligned with BRP Recommendations

Questions

Questions?




National Cancer Advisory Board February 15, 2017

Funding for Beau Biden Cancer Moonshot

FY 2021

FY 2022

FY 2023



FY 2020

FY 2017

FY 2018

FY 2019

Fiscal Year	Dollar in Millions
2017	\$300
2018	\$300
2019	\$400
2020	\$195
2021	\$195
2022	\$194
2023	\$216

Cancer Moonshot Implementation Teams

- A. Network for Direct Patient Engagement
- **B.** Cancer Immunotherapy Translational Science Network
 - **Bi. Pediatric Implementation Team**
 - **Bii. Adult Implementation Team**
- C. Therapeutic Target Identification to Overcome Drug Resistance
- D. A National Cancer Data Ecosystem for Sharing and Analysis
- **E.** Fusion Oncoproteins in Childhood Cancers
- F. Symptom Management Research
- G. Prevention and Early Detection: Implementation and Evidenced-Based Approaches
 - **Gi.** High Risk Cancers Implementation Team
 - Gii. Cancer Prevention and Screening Implementation Team
- **H. Development of New Enabling Cancer Technologies**
- I. Retrospective Analysis of Biospecimens from Patients Treated with Standard of Care
- J. Generation of Human Tumor Atlases

Implementation Team Composition and Responsibilities

- NCI Extramural Program Staff
 - Responsible for developing LOI's, concepts and initiatives for extramural funding
 - Responsible for developing funding plans and management of awards
- NCI Intramural Staff
 - Participate in a parallel intramural process for developing and vetting intramural LOIs
 - Present reviewed intramural proposals to incorporate into proposed funding plans
- Staff from other IC's
 - Participate in the discussions, identifying areas of common interest and collaboration
 - Develop proposals for collaboration and propose sign-on to RFAs to parent IC
- NCI CRS staff
 - Will provide support for Wiki page, capturing key ideas and action items from Team meetings, portfolio analysis, and other scientific support activities